Avadel Pharmaceuticals (AVDL) Q4 2024 Guidance earnings summary

Opening remarks and agenda

• Provided a business update and 2025 outlook, including launch progress, financial guidance, and lifecycle management milestones, with a focus on accelerating LUMRYZ launch and enhancing patient/provider experience.

• Outlined topics: LUMRYZ launch update, 2024 preliminary results, 2025 revenue guidance, path to $1B revenue, and lifecycle management programs.

• Business update call held on January 8, 2025, focused on LUMRYZ launch review, financial update, lifecycle management, and 2025 milestones.

• Preliminary 2024 results and 2025 commercial priorities announced.

Guidance on key objectives

• 2025 net product revenue projected at $240–$260 million, a 50% increase over 2024, with positive cash flow of $20–$40 million.

• Targeting 3,300–3,500 patients on therapy by year-end 2025 and 2,800–3,000 new patient initiations.

• Cash operating expenses for 2025 expected at $180–$200 million.

• Focus on expanding physician reach, accelerating switch patient activation, and improving patient persistence.

• Targeting 80%+ reimbursed patient mix and aiming for 8,000 reimbursed patients to reach $1B revenue over several years.

Market trends and strategic opportunities

• LUMRYZ patient base grew to 2,500 by end of 2024, up from 900 in 2023, with strong adoption across all narcolepsy patient segments.

• Over 50,000 oxybate-eligible patients in the U.S. represent a $1B+ peak sales opportunity for LUMRYZ.

• 74% of patients on therapy were reimbursed as of December 31, 2024.

• LUMRYZ holds FDA Orphan Drug Exclusivity and is the only once-at-bedtime oxybate for narcolepsy.

• Ongoing Phase 3 trial for idiopathic hypersomnia (IH) expands addressable market beyond narcolepsy.